The US Department of Justice has told an appeals court that payments made by branded pharmaceutical companies to delay competition from generic drug manufacturers are “presumptively unlawful”. Companies involved in such “pay-for-delay” deals, it said, must justify their action to avoid antitrust liability 1...
Please login to read the full article.
